Literature DB >> 28169013

Cost analysis of an outbreak of Clostridium difficile infection ribotype 027 in a Dutch tertiary care centre.

Y H van Beurden1, M K Bomers2, S D van der Werff3, E A P M Pompe4, S Spiering5, C M J E Vandenbroucke-Grauls3, C J J Mulder5.   

Abstract

BACKGROUND: The economic impact of Clostridium difficile infection (CDI) on the healthcare system is significant. From May 2013 to May 2014, an outbreak of C. difficile ribotype 027 occurred in a Dutch tertiary care hospital, involving 72 patients. The primary aim of this study was to provide insight into the financial burden that this CDI outbreak brought upon this hospital.
METHODS: A retrospective analysis was performed to estimate the costs of a one-year-long C. difficile ribotype 027 outbreak. Medical charts were reviewed for patient data. In addition, all costs associated with the outbreak control measures were collected.
FINDINGS: The attributable costs of the whole outbreak were estimated to be €1,222,376. The main contributing factor was missed revenue due to increased length of stay of CDI patients and closure of beds to enable contact isolation of CDI patients (36%). A second important cost component was extra surveillance and activities of the Department of Medical Microbiology and Infection Control (25%).
CONCLUSION: To the authors' knowledge, this is the first study to provide insight into the attributable costs of CDI in an outbreak setting, and to delineate the major cost items. It is clear that the economic consequences of CDI are significant. The high costs associated with a CDI outbreak should help to justify the use of additional resources for CDI prevention and control.
Copyright © 2016 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile infection; Costs; Economic burden; Outbreak; PCR ribotype 027

Mesh:

Year:  2016        PMID: 28169013     DOI: 10.1016/j.jhin.2016.12.019

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  7 in total

Review 1.  Is the Medium Still the Message? Culture-Independent Diagnosis of Gastrointestinal Infections.

Authors:  Neil Sood; Gary Carbell; Holly S Greenwald; Frank K Friedenberg
Journal:  Dig Dis Sci       Date:  2021-11-30       Impact factor: 3.199

2.  Surveillance of antibiotic resistance among common Clostridium difficile ribotypes in Hong Kong.

Authors:  Viola C Y Chow; Thomas N Y Kwong; Erica W M So; Yolanda I I Ho; Sunny H Wong; Raymond W M Lai; Raphael C Y Chan
Journal:  Sci Rep       Date:  2017-12-08       Impact factor: 4.379

Review 3.  Faecal microbiota transplantation: a regulatory hurdle?

Authors:  Frederick Verbeke; Yorick Janssens; Evelien Wynendaele; Bart De Spiegeleer
Journal:  BMC Gastroenterol       Date:  2017-11-28       Impact factor: 3.067

4.  Bacterial infections among patients with psychiatric disorders: Relation with hospital stay, age, and psychiatric diagnoses.

Authors:  Michael Belz; Nico Rehling; Ulrike Schmidt; Jens Wiltfang; Bernhard Kis; Claus Wolff-Menzler
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

5.  Implementation of control measures against an outbreak due to Clostridioides difficile producing toxin B in a tertiary hospital in Mexico.

Authors:  Oscar Sosa-Hernández; Bernardina Matías-Téllez; Juana González-Martínez; Rocio Juárez-Vargas; Norma Elizabeth González-González; Abril Estrada-Hernández; Monserrat Ruíz-Santana; Juan Carlos Bravata-Alcántara; Juan Manuel Bello-López
Journal:  J Prev Med Hyg       Date:  2021-07-30

6.  Cost analysis of a teaching hospital in Thailand: Impacts of the first wave of COVID-19.

Authors:  Nopphol Witvorapong; Sureerat Ngamkiatphaisan; Jiruth Sriratanaban
Journal:  PLoS One       Date:  2022-09-01       Impact factor: 3.752

7.  A Clostridium difficile outbreak in an Italian hospital: the efficacy of the multi-disciplinary and multifaceted approach.

Authors:  A M Spagnolo; M Sartini; A Battistella; B Casini; G Lo Pinto; E Schinca; M L Cristina
Journal:  J Prev Med Hyg       Date:  2018-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.